ViviGen Cellular Bone Matrix ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04007094 (ClinicalTrials.gov) | February 12, 2019 | 24/4/2019 | Single-Armed Use of ViviGen Cellular Bone Matrix in Patients Undergoing Posterolateral Lumbar Surgery | A Prospective, Single Arm Study of Patients Undergoing Posterolateral Lumbar Fusion (Without Interbody) Supplemented With ViviGen Cellular Bone Matrix | Degenerative Disc Disease;Spinal Stenosis;Spondylosis;Spondylolisthesis | Drug: ViviGen Cellular Bone Matrix | Ohio State University | DePuy Synthes | Recruiting | 18 Years | N/A | All | 50 | Phase 4 | United States |